ADC值鉴别透明细胞性肾细胞癌的诊断试验准确性:系统综述与Meta分析
该系统综述纳入48项研究(2588个病灶),Meta分析纳入13项研究(1126个病灶),评估ADC值鉴别局限性透明细胞性肾细胞癌与其他肾肿瘤类型的诊断性能。排除囊性和坏死区域的选择性ADC(sADC)鉴别ccRCC的AUC为0.852,高于全病灶ADC(wADC)的0.785(p=0.02),sADC敏感度80%、特异度78%。
要点
- 排除囊性和坏死区域的选择性ADC(sADC)鉴别ccRCC的AUC为0.852,高于全病灶ADC的0.785(p=0.02)。
- sADC鉴别ccRCC的汇总敏感度为80%、特异度为78%,属于中等诊断性能。
- b值取0-800与0-1000时肾实质ADC无显著差异(p=0.08),两种b值下sADC均优于wADC。
核心结论
- 排除囊性和坏死区域的肾脏肿瘤ADC值(sADC)较全病灶ADC值(wADC)能更准确地将ccRCC与其他肾肿瘤类型区分开。
研究设计与样本
- 系统综述纳入48项研究(2588个病灶),Meta分析纳入13项研究(1126个病灶),检索Medline、Embase和Cochrane Library截至2019年5月1日发表的文献。
- 对ADC鉴别ccRCC与其他肾病灶的诊断试验准确性采用双变量随机效应模型进行Meta分析,并比较测量ADC时包含与不包含囊性和坏死区域两个亚组。
- 对纳入研究的方法学质量进行了评价。
关键影像表现/征象
- 与ccRCC相比,乏脂肪血管平滑肌脂肪瘤、乳头状RCC和嫌色细胞RCC的sADC显著更低,而嗜酸细胞瘤的sADC更高。
诊断标准与关键数值
- sADC鉴别ccRCC与其他肿瘤的汇总敏感度为80%(95%CI 0.76-0.88),特异度为78%(95%CI 0.64-0.89)。
- wADC鉴别ccRCC与其他肿瘤的汇总敏感度为77%(95%CI 0.59-0.90),特异度为77%(95%CI 0.69-0.86)。
- sADC的受试者工作特征曲线下面积高于wADC(0.852 vs. 0.785,p=0.02)。
- 肾实质ADC在使用b值0-800与0-1000时无显著差异(p=0.08);排除囊性和坏死区域测量的sADC与wADC差异显著(p=0.002)。
临床应用与阅片要点
- 作者结论认为,排除囊性和坏死区域的ADC值较全病灶ADC值能更准确鉴别ccRCC与其他肾肿瘤类型。
- 作者要点指出,sADC作为多期MRI的附加工具,在最高b值为800或1000时均优于wADC,用于鉴别ccRCC与其他肾病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To perform a systematic review on apparent diffusion coefficient (ADC) values of renal tumor subtypes and meta-analysis on the diagnostic performance of ADC for differentiation of localized clear cell renal cell carcinoma (ccRCC) from other renal tumor types.
METHODS: Medline, Embase, and the Cochrane Library databases were searched for studies published until May 1, 2019, that reported ADC values of renal tumors. Methodological quality was evaluated. For the meta-analysis on diagnostic test accuracy of ADC for differentiation of ccRCC from other renal lesions, we applied a bivariate random-effects model and compared two subgroups of ADC measurement with vs. without cystic and necrotic areas.
RESULTS: We included 48 studies (2588 lesions) in the systematic review and 13 studies (1126 lesions) in the meta-analysis. There was no significant difference in ADC of renal parenchyma using b values of 0-800 vs. 0-1000 (p = 0.08). ADC measured on selected portions (sADC) excluding cystic and necrotic areas differed significantly from whole-lesion ADC (wADC) (p = 0.002). Compared to ccRCC, minimal-fat angiomyolipoma, papillary RCC, and chromophobe RCC showed significantly lower sADC while oncocytoma exhibited higher sADC. Summary estimates of sensitivity and specificity to differentiate ccRCC from other tumors were 80% (95% CI, 0.76-0.88) and 78% (95% CI, 0.64-0.89), respectively, for sADC and 77% (95% CI, 0.59-0.90) and 77% (95% CI, 0.69-0.86) for wADC. sADC offered a higher area under the receiver operating characteristic curve than wADC (0.852 vs. 0.785, p = 0.02).
CONCLUSIONS: ADC values of kidney tumors that exclude cystic or necrotic areas more accurately differentiate ccRCC from other renal tumor types than whole-lesion ADC values.
KEY POINTS: • Selective ADC of renal tumors, excluding cystic and necrotic areas, provides better discriminatory ability than whole-lesion ADC to differentiate clear cell RCC from other renal lesions, with area under the receiver operating characteristic curve (AUC) of 0.852 vs. 0.785, respectively (p = 0.02). • Selective ADC of renal masses provides moderate sensitivity and specificity of 80% and 78%, respectively, for differentiation of clear cell renal cell carcinoma (RCC) from papillary RCC, chromophobe RCC, oncocytoma, and minimal-fat angiomyolipoma. • Selective ADC excluding cystic and necrotic areas are preferable to whole-lesion ADC as an additional tool to multiphasic MRI to differentiate clear cell RCC from other renal lesions whether the highest b value is 800 or 1000.
引用
- Tordjman M, Mali R, Madelin G, et al. Diagnostic test accuracy of ADC values for identification of clear cell renal cell carcinoma: systematic review and meta-analysis. Eur Radiol. 2020. PMID: 32144458. doi:10.1007/s00330-020-06740-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。